65892 Federal Register / Vol. 77, No. 211 / Wednesday, October 31, 2012 / Notices 

Comments submitted in response to 

this notice will be summarized and 

included in the Agency’s subsequent 

request for OMB approval of the 

proposed information collection. All 

comments will become a matter of 

public record. 

Dated: October 12, 2012. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2012–26596 Filed 10–30–12; 8:45 am] 

BILLING CODE M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meeting 

AGENCY: Agency for Healthcare Research 

and Quality, HHS. 

ACTION: Notice. 

SUMMARY: In accordance with section 10 

(a)(2) of the Federal Advisory 

Committee Act (5 U.S.C. App. 2), 

announcement is made of an Agency for 

Healthcare Research and Quality 

(AHRQ) Special Emphasis Panel (SEP) 

meeting on ‘‘AHRQ NATIONAL 

RESEARCH SERVICE AWARDS (NRSA) 

INSTITUTIONAL RESEARCH 

TRAINING GRANTS (T32)’’. 

DATES: November 14–15, 2012 (Open on 

November 14 from 8:00 a.m. to 8:30 a.m. 

and closed for the remainder of the 

meeting). 

ADDRESSES: Gaithersburg Marriott, RIO, 

9751 Washingtonian Boulevard, 

Gaithersburg, MD 20878. 

FOR FURTHER INFORMATION CONTACT: 

Anyone wishing to obtain a roster of 

members, agenda or minutes of the nonconfidential portions of this meeting 

should contact: Mrs. Bonnie Campbell, 

Committee Management Officer, Office 

of Extramural Research, Education and 

Priority Populations, AHRQ, 540 

Gaither Road, Room 2038, Rockville, 

Maryland 20850, Telephone: (301) 427– 

1554. 

Agenda items for this meeting are 

subject to change as priorities dictate. 

SUPPLEMENTARY INFORMATION: A Special 

Emphasis Panel is a group of experts in 

fields related to health care research 

who are invited by the Agency for 

Healthcare Research and Quality 

(AHRQ), and agree to be available, to 

conduct on an as needed basis, 

scientific reviews of applications for 

AHRQ support. 

Individual members of the Panel do 

not attend regularly-scheduled meetings 

and do not serve for fixed terms or a 

long period of time. Rather, they are 

asked to participate in particular review 

meetings which require their type of 

expertise. 

Substantial segments of the SEP 

meeting referenced above will be closed 

to the public in accordance with the 

provisions set forth in 5 U.S.C. App. 2, 

section 10(d), 5 U.S.C. 552b(c)(4), and 5 

U.S.C. 552b(c)(6). Grant applications for 

‘‘AHRQ NATIONAL RESEARCH 

SERVICE AWARDS (NRSA) 

INSTITUTIONAL RESEARCH 

TRAINING GRANTS (T32)’’ are to be 

reviewed and discussed at this meeting. 

The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Dated: October 12, 2012. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2012–26597 Filed 10–30–12; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Patient Safety Organizations: 

Voluntary Relinquishment From PDR 

Secure, LLC 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice of Delisting. 

SUMMARY: The Patient Safety and 

Quality Improvement Act of 2005 

(Patient Safety Act), Public Law 109–41, 

42 U.S.C. 299b–21–b–26, provides for 

the formation of Patient Safety 

Organizations (PSOs), which collect, 

aggregate, and analyze confidential 

information regarding the quality and 

safety of health care delivery. The 

Patient Safety and Quality Improvement 

Final Rule (Patient Safety Rule), 42 CFR 

Part 3, authorizes AHRQ, on behalf of 

the Secretary of HHS, to list as a PSO 

an entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ by 

the Secretary if it is found no longer to 

meet the requirements of the Patient 

Safety Act and Patient Safety Rule, or 

when a PSO chooses to voluntarily 

relinquish its status as a PSO for any 

reason. AHRQ has accepted a 

notification of voluntary relinquishment 

from PDR Secure, LLC of its status as a 

PSO, and has delisted the PSO 

accordingly. 

DATES: The directories for both listed 

and delisted PSOs are ongoing and 

reviewed weekly by AHRQ. The 

delisting was effective at 12:00 Midnight 

ET (2400) on August 31, 2012. 

ADDRESSES: Both directories can be 

accessed electronically at the following 

HHS Web site: http:// 

www.pso.AHRQ.gov/index.html. 

FOR FURTHER INFORMATION CONTACT: 

Eileen Hogan, Center for Quality 

Improvement and Patient Safety, AHRQ, 

540 Gaither Road, Rockville, MD 20850; 

Telephone (toll free): (866) 403–3697; 

Telephone (local): (301) 427–1111; TTY 

(toll free): (866) 438–7231; TTY (local): 

(301) 427–1130; Email: 

pso@AHRQ.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

The Patient Safety Act authorizes the 

listing of PSOs, which are entities or 

component organizations whose 

mission and primary activity is to 

conduct activities to improve patient 

safety and the quality of health care 

delivery. 

HHS issued the Patient Safety Rule to 

implement the Patient Safety Act. 

AHRQ administers the provisions of the 

Patient Safety Act and Patient Safety 

Rule (PDF file, 450 KB. PDF Help) 

relating to the listing and operation of 

PSOs. The Patient Safety Rule 

authorizes AHRQ to list as a PSO an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ if 

it is found no longer to meet the 

requirements of the Patient Safety Act 

and Patient Safety Rule, or when a PSO 

chooses to voluntarily relinquish its 

status as a PSO for any reason. Section 

3.108(d) of the Patient Safety Rule 

requires AHRQ to provide public notice 

when it removes an organization from 

the list of federally approved PSOs. 

AHRQ has accepted a notification 

from PDR Secure, LLC, PSO number 

P0098, which is a component entity of 

PDR Network, LLC, to voluntarily 

relinquish its status as a PSO. 

Accordingly, PDR Secure, LLC was 

delisted effective at 12:00 Midnight ET 

(2400) on August 31, 2012. PDR 

Network, LLC represents that it has 

patient safety work product (PSWP) in 

its possession. The PSO is obligated to 

meet the requirements of section 

3.108(c)(2)(i) of the Patient Safety Rule 

to notify the sources from which it 

received PSWP of the PSO’s intention to 

cease PSO operations and activities, to 

relinquish voluntarily its status as a 

PSO, to request that these other entities 


tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 211 / Wednesday, October 31, 2012 / Notices 65893 

cease reporting or submitting any 

further information to the PSO as soon 

as possible, and to inform them that any 

information reported after the effective 

date and time of delisting will not be 

protected as PSWP under the Patient 

Safety Act. In addition, according to 

section 3.108(c)(2)(ii) of the Patient 

Safety Rule regarding disposition of 

PSWP, the PSO has 90 days from the 

effective date of delisting and revocation 

to complete the disposition of PSWP 

that is currently in the PSO’s 

possession. 

More information on PSOs can be 

obtained through AHRQ’s PSO Web site 

at http://www.pso.AHRQ.gov/ 

index.html. 

Dated: October 12, 2012. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2012–26598 Filed 10–30–12; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60-Day–13–0488] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–7570 and 

send comments to Ron Otten, CDC 

Reports Clearance Officer, 1600 Clifton 

Road, MS–D74, Atlanta, GA 30333 or 

send an email to omb@cdc.gov. 

Comments are invited on (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have a 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of information technology. Written 

comments should be received within 60 

days of this notice. 

Proposed Project 

Restriction on Interstate Travel of 

Persons (OMB Control No. 0920–0488 

Exp. 3/31/2013)—Revision—National 

Center Emerging and Zoonotic 

Infectious Diseases (NCEZID), Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention is requesting OMB approval 

to extend the information collection 

request, ‘‘Restriction on Interstate Travel 

of Persons’’ (OMB Control No. 0920– 

0488). 

This information collection request is 

scheduled to expire on March 31, 2013. 

CDC is authorized to collect this 

information under 42 CFR 70.5 (Certain 

communicable diseases; special 

requirements). This regulation requires 

that any person who is in the 

communicable period for cholera, 

plague, smallpox, typhus, or yellow 

fever or having been exposed to any 

such disease is in the incubation period 

thereof, to apply for and receive a 

permit from the Surgeon General or his 

authorized representative in order to 

travel from one State or possession to 

another. 

Control of disease transmission 

within the States is considered to be the 

province of state and local health 

authorities, with Federal assistance 

being sought by those authorities on a 

cooperative basis without application of 

Federal regulations. The regulations in 

42 Part 70 were developed to facilitate 

Federal action in the event of large 

outbreaks requiring a coordinated effort 

involving several states, or in the event 

of inadequate local control. While it is 

not known whether, or to what extent 

situations may arise in which these 

regulations would be invoked, 

contingency planning for domestic 

emergency preparedness is now 

commonplace. Should these situations 

arise, CDC will use the reporting and 

recordkeeping requirements contained 

in the regulations to carry out 

quarantine responsibilities as required 

by law. 

There is no cost to respondents other 

than their time. 

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Traveler ............................................. 42 CFR 70.3 Application to the 

State of destination for a permit.

2,000 1 15/60 500 

Attending physician ........................... 42 CFR 70.3 Copy of material submitted by applicant and permit 

issued by State health authority.

2,000 1 15/60 500 

State health authority ........................ 42 CFR 70.3 Copy of material submitted by applicant and permit 

issued by State health authority.

8 250 6/60 200 

Master of a vessel or person in 

charge of a conveyance.

42 CFR 70.4 Report by specified 

respondent of a communicable 

disease during interstate travel 

(Paper Form if requested by CDC 

during public health emergency).

1,500 1 15/60 375 

State health authority ........................ 42 CFR 70.4 Copy of material submitted to state/local authority 

(Paper Form if requested by CDC, 

public health emergency).

20 75 6/60 150 

Master of a vessel or person in 

charge of a conveyance.

42 CFR 70.4 Report by specified 

respondent of a communicable 

disease during interstate travel 

(Radio or other telecommunication for routine reporting).

200 1 15/60 50 


tkelley on DSK3SPTVN1PROD with NOTICES